Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ZY-A001
- Development stage
- Phase 3
- Lead developer
- Yabao Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
ZY-A001 is an investigational small molecule antiviral agent developed by Yabao Pharmaceutical Group for the treatment of acute upper respiratory tract infections (AURTI). It is classified as a Class 1 innovative chemical drug in China and specifically targets the human parainfluenza virus (HPIV), a common pathogen responsible for respiratory distress in pediatric and immunocompromised populations. ZY-A001 is designed to inhibit viral activity, potentially by interfering with viral entry or replication processes, thereby reducing the severity and duration of respiratory symptoms. The drug has progressed into Phase 1 clinical trials in China to evaluate its safety, tolerability, and pharmacokinetic profile in healthy volunteers and patients.
Beyond the preview
Go deeper on ZY-A001.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ZY-A001.